Advisory Committee To Review Disease Modifying Claim For Teva's Parkinson's Drug
This article was originally published in The Pink Sheet Daily
Executive Summary
In large early Parkinson's trial, one dose worked but another did not. Review will show how results from innovative trial will be received by FDA.
You may also be interested in...
Data For Teva's Azilect Not Good Enough For Claim Of Slowing Parkinson's Progression, FDA Panel Says
FDA advisory committee reluctant to set precedent for disease modification indication without strong data.
Data For Teva's Azilect Not Good Enough For Claim Of Slowing Parkinson's Progression, FDA Panel Says
FDA advisory committee reluctant to set precedent for disease modification indication without strong data.
Parkinson’s Disease At A Crossroad: Deals And Emerging Therapeutics
The last five years have seen an explosion in novel approaches to Parkinson’s disease.